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Abstract 
The α4β2 nicotinic acetylcholine receptor (nAChR) is a molecular target of 3,4-
methylenedioxymethamphetamine (MDMA), a synthetic drug also known as ecstasy, and it modulates the 
MDMA-mediated reinforcing properties. However, the enantioselective preference of the α4β2 nAChR 
subtype still remains unknown. Since the two enantiomers exhibit different pharmacological profiles and 
stereoselective metabolism, the aim of this study is to assess a possible difference in the interaction of the 
MDMA enantiomers with this nAChR subtype. To this end, we report a novel simple, yet highly efficient 
enantioselective synthesis of the MDMA enantiomers, in which the key step is the diastereoselective 
reduction of imides derived from optically pure tert-butylsulfinamide. The enantioselective binding to the 
receptor is examined using [
3
H]epibatidine in a radioligand assay. Even though the two enantiomers 
induced a concentration-dependent binding displacement, (S)-MDMA has an inhibition constant 13-fold 
higher than (R)-MDMA, which shows a Hill‟s coefficient not significantly different from unity, implying 
a competitive interaction. Furthermore, when NGF-differentiated PC12 cells were pretreated with the 
compounds, a significant increase in binding of [
3
H]epibatidine was found for (R)-MDMA, indicating up-
regulation of heteromeric nAChR in the cell surface. Finally, docking and molecular dynamics studies 
have been used to identify the binding mode of the two enantiomers, which provides a structural basis to 
justify the differences in affinity from the differential interactions played by the substituents at the 
stereogenic center of MDMA. The results provide a basis to explore the distinct psychostimulant profiles 
of the MDMA enantiomers mediated by the α4β2 nAChR subtype. 
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1. Introduction 
3,4-Methylenedioxymethamphetamine (MDMA; Scheme 1), also known as ecstasy, is a synthetic drug 
widely abused in the United States and Europe, where it is taken in a recreational context due to its 
stimulant and hallucinogenic properties. Amphetamines produce a dose-dependent increase of locomotor 
activity in rodents [1], which reflects an increase of dopamine (DA) transmission in the nucleus 
accumbens [2]. Activation of nicotinic acetylcholine receptors (nAChRs) is a common event in the 
pathway used by several addictive drugs to stimulate the mesolimbic DA system, which is a relevant 
component of the brain stimulation reward pathway [3,4]. Thus, in rats systemic nicotine or alcohol 
administration elevates extracellular DA levels in the nucleus accumbens, an effect that requires 
stimulation of nAChRs in this area as well as in the ventral tegmental one, in which the mesolimbic 
dopaminergic cell bodies are located [5–7]. 
The heteromeric α4β2 nAChR subtype, which is involved in regulating the nicotine dependence [8], is 
strongly associated with DA release in the nucleus accumbens [9] and with drug-seeking behaviour 
[10,11]. Therefore, it is generally assumed that the α4β2 nAChR subtype plays a major role in reinforcing 
the effects of nicotine and has been recognized as a major target in addictive pathologies. This is reflected 
in the hypothesis that the main addictive drugs with psychostimulant properties share the capacity to 
interact with α4β2 receptors [12,13] In this regard, the α4β2 nAChR subtype can also explain the 
mechanism of other reinforcing substances. A particular feature of nAChR is that chronic exposure to 
nicotinic ligands induces a higher level of epibatidine (Scheme 1) binding to β2-containing nAChRs, 
leading to a functional up-regulation [14–16] that should enhance the addictive effects of these 
compounds [8]. This phenomenon is independent of de novo protein synthesis. Vallejo et al. [17] 
demonstrated that α4β2-subtype receptors exist in two interconvertible states, with high and with low 
affinities for nicotine, respectively, and that chronic exposure to a nAChR ligand stabilizes a larger fraction of 
receptors in the high-affinity state at the membrane surface. Other authors [18,19] suggest a chaperone- 
maturation enhancing effect of nicotine on immature receptors inhibiting its degradation. This is not related to the 
efficacy of the ligand in activating the receptor but to its affinity. 
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We have demonstrated that nAChRs are a pharmacological target for MDMA and mediate some actions 
of this drug of abuse [20,21] including analgesia or locomotor activity [22], tumor necrosis factor alpha 
suppression [23] and neurotoxicity [24–26]. Recently, Ciudad-Roberts et al. [27] established that the 
α4β2 nAChR subtype modulates MDMA-mediated reinforcing properties. Previous studies [20,28] had 
also shown that MDMA has affinity for α4β2 nAChR and induced their up-regulation in PC12 cells 
following a similar mechanism than that of nicotine. Lately it was reported that rat exposure to nicotine or 
MDMA each induced significant increases in [
3
H]epibatidine binding (about 30 and 35%, respectively) 
with respect to saline-treated rats, and that this effect was significantly potentiated (up to 72%) when the 
two drugs were associated [21] . Consequently, knowledge of the interaction of MDMA with nAChRs is 
valuable to understand the role of this receptor in both nicotine and psychostimulant addictions. 
MDMA contains a stereogenic center at the carbon α to the amine (Scheme 1). Even though it is 
consumed as a racemate, the two enantiomers exhibit different pharmacological profiles and 
stereoselective metabolism [29,30]. Thus, in vitro models have revealed that (S)-MDMA is more active 
than (R)-MDMA on the central nervous system (CNS) [31–34]. On the other hand, MDMA is known to 
undergo extensive hepatic metabolism, leading to the formation of highly redox-active metabolites that 
have been implicated in MDMA-induced hepato-, neuro-, nephron- and cardiotoxicity [35,36]. However, 
these effects are sensitive to the enantiomeric form of MDMA. For instance, (R)-MDMA primarily 
contributes to the depletion of the hepatic glutathione induced by the racemic mixture [37]. Moreover, 
studies in animal models revealed that (S)-MDMA rather than (R)-MDMA contributes to the serotonergic 
injury and astroglial and microglial activation associated with MDMA consumption [38,39]. Finally, rac-
MDMA exerts simultaneous effects, reducing L-DOPA-induced dyskinesia and extending its 
antiparkinsonian benefits (ON-time) by 5-HT2A antagonism and serotonin transporter selective inhibition, 
which arise from its R and S enantiomers, respectively [40]. 
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The aim of this study is to characterize for the first time the interaction of the two enantiomeric forms of 
MDMA upon binding to the α4β2 nAChR subtype, and to explore the molecular basis of the selective 
binding to this receptor. To this end, we have examined a novel and efficient strategy for the synthesis of 
both enantiomers of MDMA based on the diastereomeric reduction of the imides derived from optically 
pure tert-butylsulfinamide. Afterwards, we have evaluated the experimental affinity of both enantiomers 
for the α4β2 nAChR using radioligand binding assays. Attention has also been paid to the differential 
effects of the two enantiomers in triggering the α4β2 nAChR up-regulation. Finally, molecular modelling 
and computational techniques have been used to study the interaction with the α4β2 nAChR subtype and 
to identify the molecular determinants responsible of the different affinity of the enantiomeric forms of 
MDMA. 
 
2. Results and discussion 
2.1. Synthesis of MDMA enantiomers 
Several enantioselective syntheses of amphetamines have been reported [41–45]. The first stereoselective 
synthesis of MDMA was based on the hydrogenation of imines derived from 1-phenylethylamine as a 
chiral auxiliary [41]. The same quiral auxilliary was used by Pizarro et al. in the preparation of 
enantiomerically enriched HMMA (4-hydroxy-3-methoxymethamphetamine) and HHMA (3,4-
dihydroxymethamphetamine) [42]. An enzymatic methodology was reported for the preparation of chiral 
cyanohydrins that were transformed into 3,4-methylenedioxyamphetamines [43]. Wagner et al. reported a 
stereoespecific synthesis of amphetamines, although it was not applied to MDMA [44]. Recently, Huot et 
al. published another synthesis of MDMA enantiomers by enantiospecific ring opening of aziridines with 
a Grignard reagent, even though the experimental details have not been described [40]. These synthetic 
approaches are not practical since they involve either low diastereoselectivities, costly preparation of the 
starting ketones or lack of experimental procedures. Therefore, we have developed a new and efficient 
synthesis of both enantiomers of MDMA based on the diastereomeric reduction of the imides derived 
from optically pure tert-butylsulfinamide. 
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Our synthesis started from commercially available 3,4-dibenzyloxybenzaldehyde (1), which was 
transformed into the methyl ketone 3 by condensation with nitroethane followed by reduction with 
Fe/HCl (Scheme 2). The corresponding imine, formed by treatment of ketone 3 with (R)-(+)-tert-
butylsulfinamide and Ti(OEt)4 was reduced in situ with NaBH4 at room temperature to afford the two 
diastereomeric sulfinamides 4 in excellent yield but with moderate (3:1) diastereomeric ratio. Gratifyingly, 
the diastereoselectivity rose to 14:1 by lowering the temperature to -20ºC in the reduction step. The major 
isomer was easily purified by crystallization from hexane affording diastereomerically pure (R,RS)-4a as 
a white solid (Scheme 2). 
Methylation of sulfonamide (R,RS)-4a was carried out uneventfully with NaH and MeI in DMF at room 
temperature to give (R,RS)-5a in 90% yield. However, we were unable to cleave the benzyloxy groups by 
catalytic hydrogenation (Pd/C) even at high hydrogen pressures (50 bar) and/or temperatures (50 ºC). We 
hypothesized that sulphur byproducts derived from sulfinimides hampered the reaction poisoning the 
catalyst (Scheme 3). Alternatively, derivatization of (R,RS)-4a as ethyl carbamate was unsuccessful since 
this sulfonamide is a very weak nucleophile. Therefore, we envisaged the hydrolysis of (R,RS)-4a to the 
primary amine. Reductive cleavage of N-S bond was easily performed with 4M MeOH/HCl in dioxane 
affording amine (R)-6a in 94% yield. Formation of the carbamate of the primary amine (R)-7a was 
carried out with ClCO2Et, Et3N in DMF. This compound was highly crystalline and allowed to confirm 
its high optical purity (99%ee by chiral HPLC). Cleavage of the dibenzyloxy group in (R)-7a could be 
performed by hydrogenolysis and the resulting diphenol was cyclized with bromochloromethane and 
cesium carbonate as described by Pizarro et al. [42]. Finally, reduction with lithium aluminum hydride in 
THF yielded the desired compound (R)-10a (MDMA) in 85% yield, which was isolated as a 
hydrochloride. The enantiomeric purity of the final product was checked by chiral HPLC of the 
corresponding N-Boc derivative, being 99% ee, as expected. Since both enantiomers of tert-
butylsulfinamide are commercially available, the same sequence starting from (S)-(–)-tert-
butylsulfinamide afforded the (S)-MDMA enantiomer also in 99%ee. 
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2.2. Experimental binding affinity of MDMA enantiomers 
When [
3
H]epibatidine was used as a radioligand to label the α4β2 nAChR subtype, all the compounds 
induced a concentration-dependent binding displacement, with IC50 values in the micromolar range (see 
Figure 1 and Table 1), indicating that they can directly interact with the nicotinic receptor. The affinity of 
(R)-MDMA for the [
3
H]epibatidine binding site was higher than (S)-MDMA, as noted in the 13-fold ratio 
between the inhibition constants (Ki) determined for both enantiomers, respectively (see Table 1). The Ki 
value of (R)-MDMA is in the submicromolar range (Ki = 0.63), which thus compares with the low 
micromolar concentrations found in the brain after administration of this drug [45,46] . In fact, the 
binding constant for this heteromeric receptor is lower than the Ki value determined for the serotonin 
transporter, which is its main physiological target (24.5 μM) [40]. 
 
The Hill coefficients resulting from the analysis of competition data of (R)-MDMA or rac-MDMA versus 
[
3
H]epibatidine were not significantly different from unity, pointing to a competitive displacement. In 
contrast, the Hill‟s coefficient for (S)-MDMA was significantly less than unity, suggesting a more 
complex interaction. 
 
2.3. Up-regulation of heteromeric nAChR by MDMA enantiomers 
Once established the affinity constants, we tested whether these compounds had any effect on α4β2 
nAChR up-regulation. When NGF-differentiated PC12 cells were pretreated with (R)-MDMA, (S)-
MDMA or the racemic mixture for 24 h, at a concentration of 100 μM, a significant increase in binding of 
[
3
H]epibatidine was found for (R)-MDMA and rac-MDMA, indicating up-regulation of heteromeric 
nAChR. It is known that this up-regulation is independent of de novo protein synthesis [47] but it is 
consistent with a higher ratio of the high-affinity component of [
3
H]epibatidine binding [17], as suggested 
by previous studies on chronic exposure to nicotine [28] . This effect was significantly higher for (R)-
 9 
MDMA than for the racemic mixture (see Figure2). (S)-MDMA did not significantly modify the nAChR 
population. These results support the direct interaction with nAChR reported above and corroborates the 
higher affinity of (R)-MDMA compared with (S)-MDMA. 
 
2.4. Binding mode of MDMA 
Previous studies have indicated that the nicotinic binding site is located at the centre of the extracellular 
domain of the receptor and lies at the interface between  and β subunits, which are known as the 
principal (P) and complementary (C) components, respectively [48–50]. Several residue stretches referred 
to as loops A, B and C in the  subunit, and D, E and F in the β subunit shape the binding site (in the 
following the symbols "" and "β" will be used before the residue to indicate the subunit it belongs to, 
and the numbering refers to the 4 and β2 subunits in rat). Conserved residues at the binding site are the 
aromatic amino acids Tyr128 (loop A), Trp184 and Tyr186 (loop B), Tyr225 and Tyr232 (loop C) 
and βTrp81 (loop D). Residues βVal135, βPhe143 and βLeu145 shape the top of the binding site. The 
bridged cysteine residues in loop C (Cys227 and Cys228) are present only in the α-subunit.  
The binding mode of epibatidine, (R)-MDMA and (S)-MDMA was examined by means of docking 
calculations with MOE (Chemical Computing Group). The predicted pose of epibatidine nicely 
reproduced the binding mode observed in the X-ray structure (PDB entries 2BYQ [51] and 3SQ6 [52]), 
thus giving confidence to the docking protocol. In particular, the binding mode reproduced the cation-pi 
interaction with the indole ring of Trp184 (corresponding to Trp147 in 2BYQ) and the hydrogen bond 
with the carbonyl unit of this residue (see Figure S1 in Supporting Information). It is worth noting that 
these interactions are crucial for modulating the affinity of nicotine toward brain and muscle receptor 
subtypes [53]. Recent studies have also highlighted the relevance of the hydrogen bond with the backbone 
carbonyl of Trp184 for the binding of ligands to nAChRs [54]. 
For (R)-MDMA the best pose (denoted BP hereafter; MOE score: -6.7 kcal/mol) obtained in docking 
calculations nicely matches the structure of epibatidine, as noted in the superposition of the protonated 
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secondary nitrogen atoms and the overlap between the chloropiperidine and methylenedioxybenzene 
moieties of these compounds (see Figure 3A). The analysis of the results also showed an alternative pose 
(designated AP; MOE score: -4.9 kcal/mol) that retains the interaction of the secondary amine with 
Trp184, but the methylenedioxybenzene ring adopts a different orientation and fills the region located 
between the disulfide bridge formed by Cys227-Cys228 and βPhe143 (Figure 3B).  
Docking of (S)-MDMA led to similar binding modes as those described for (R)-MDMA (see Figure S2 in 
Supporting Information). The scores of the two poses (MOE scores of -6.4 and -5.1 kcal/mol for BP and 
AP solutions, respectively) compare well with those found for (R)-MDMA, thus reflecting the similar 
arrangement of the protonated nitrogen atom and the methylenedioxybenzene unit in the binding site for 
the equivalent poses of both (R)- and (S)-MDMA.  
 
2.5. Structural basis of the enantioselective binding. 
MD simulations were run to examine the structural integrity of the two binding modes (BP, AP) found for 
(R)- and (S)-MDMA. For (R)-MDMA, the simulation started from the BP binding mode (Figure 3A; 
designated MD-BP) remained stable along the whole trajectory, as noted in the lack of significant 
alterations in the positional root-mean square-deviation for the residues that shape the binding site 
(RMSD ~ 1.9 Å). In contrast, when the AP binding mode (Figure 3B; denoted MD-AP) was used as the 
starting structure, a fast rearrangement was observed for the ligand, which adopted the BP binding mode 
for the rest of the trajectory. The ligand is closely packed in the binding site, forming interactions that are 
preserved along the whole trajectory (Figure 4). Thus, the secondary amine nitrogen is located at around 
3.3 Å from the indole ring of Trp184 and maintains the hydrogen bond with the carbonyl group (average 
distance of 2.9 Å). In addition, the amine nitrogen forms a hydrogen bond with the hydroxyl group of 
Tyr128, which in turn is hydrogen-bonded to the carbonyl oxygen of Ser183. The 
methylenedioxybenzene moiety fills a hydrophobic cavity formed by Thr185, Phe338, Val135, 
Phe143, Trp144 and Leu145. The methyl group in the ethylamine chain faces the six-membered rings 
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of Trp184 and βTrp81 (average distance of 3.7 Å), and the phenol ring of Tyr128 (at 4.0 Å). The 
ethylene chain forms van der Waals contacts with the disulfide bridge (at around 3.5 Å). Finally, the N-
bound methyl interacts with the aromatic ring of Tyr225 and Tyr232 (average distance of 3.9 and 3.5 
Å, respectively). Overall, the consistency of the binding modes found in the two independent trajectories 
supports the binding mode proposed for (R)-MDMA. 
The trajectories run for the two binding modes of (S)-MDMA did not converge to a common binding 
mode, and the ligand retained the distinct orientation of the methylenedioxybenzene unit. In agreement 
with docking results, SIE calculations favors the BP binding mode by 0.7 kcal/mol, which reflects the 
enhanced van der Waals component due to the deeper insertion of the methylenedioxybenzene unit in the 
binding site (Table S1). Noteworthy, a common feature in the two simulations is the insertion of a water 
molecule that fills the region between the secondary amine nitrogen and the indole rings of Trp184 and 
βTrp81 (Figure S3). The entrance of the water molecule takes place through the passage shaped by 
βPhe143 and the disulfide bridge between Cys227 and Cys228 in loop C, which is more flexible in the 
presence of (S)-MDMA (Figure S4).  
The origin of the different behaviour found for the two enantiomeric species can be attributed to the 
specific interactions formed by the methyl group bound to the stereogenic center in MDMA. Thus, for 
(R)-MDMA the methyl group is tightly packed against Trp184 and βTrp81. This position, however, is 
filled by the water molecule in the complex with (S)-MDMA, whereas the methyl group fills a pocket 
formed by the disulfide bridge and residues Tyr225 and Tyr232 (Figure 5). Overall, these findings 
suggest that the specific orientation of the methyl group in (S)-MDMA makes the loop C to adopt a less 
stable fold onto the ligand in the binding pocket, which would exhibit larger fluctuations compared to the 
binding of (R)-MDMA. Since the loop C appears to behave as an „induced-fit sensor‟ that can adapt its 
conformation to the structural features of the ligand bound to the receptor [51], the largest flexibility 
observed for (S)-MDMA might thus be related to the weaker binding compared to (R)-MDMA. 
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2.6. Relative affinities between MDMA enantiomers 
To calibrate the reliability of the BP binding mode for both (R)- and (S)-MDMA, the relative affinity of 
the two enantiomers was estimated from QM/MM calculations using suitable thermodynamic cycles 
(Figure S5). The QM/MM interaction energy between ligand and receptor was found to favour the 
binding of (R)-MDMA by 3.2 kcal/mol with regard to the monohydrated S enantiomer. This contribution 
mainly comes from the van der Waals term, which favours the binding of the R enantiomer by 4.6 
kcal/mol, suggesting a tighter packing of (R)-MDMA in the binding pocket. For the S enantiomer, 
however, the QM/MM interaction energy must be corrected by the contribution due to the formation of 
the (S)-MDMA-water complex, which was estimated to be -11.4 kcal/mol (at the MP2 level with 
inclusion of the basis set superposition correction). This contribution, nevertheless, must be corrected by 
the entropic change due to formation of the monohydrated (S)-MDMA, which is estimated to be +8.0 
kcal/mol at 298 K, and by the contribution due to the vaporization of the water molecule from liquid, 
which amounts to +2.1 kcal/mol. By taking into account these corrections, the formation of the (S)-
MDMA-water complex is estimated to be -1.3 kcal/mol. Accordingly, the binding of (R)-MDMA is 
predicted to be favored by 1.9 kcal/mol, which compares well with the free energy difference determined 
from the inhibition constants reported in Table 1 (estimated to be -1.5 kcal/mol).  
 
4. Conclusions 
Since the two enantiomers of MDMA exhibit different pharmacological profiles and stereoselective 
metabolism, it is necessary to discern the different mechanism associated with the enantioselective 
activity of the two enantiomeric forms of this drug, specifically regarding to its interaction with the 
nicotinic acetylcholine receptor. To this end, this study reports a new and efficient synthesis of both 
enantiomers of MDMA based on the diastereomeric reduction of the imides derived from optically pure 
tert-butylsulfinamide, which provides a simple, yet practical way of obtaining the two enantiomers of 
MDMA. The experimental data point out that the α4β2 nicotinic receptor has larger binding affinity for 
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(R)-MDMA than for (S)-MDMA, as noted by the 13-fold ratio between the inhibitions constants 
determined in radiolabeled assays. The enantioselective binding of (R)-MDMA is consistent with the 
enhanced up-regulation of the α4β2 nAChR subtype determined in PC12 cultured cells. Therefore, these 
results indicate that (R)-MDMA is the main effector of the effects mediated by this receptor subtype. The 
molecular modelling studies point out that the two enantiomers adopt a similar arrangement in the 
binding pocket of the receptor, even though there are significant differences regarding the interactions of 
the methyl group bound to the stereogenic center. As a result, the loop C exhibits larger fluctuations in the 
presence of (S)-MDMA, which facilitates the access of water molecules that mediate the binding of the 
ligand, whereas a tighter interaction is found for (R)-MDMA. Overall, this provides a structural basis to 
pursue the development of novel compounds useful to understand the reinforcing properties of MDMA.  
 
 
 
 
5. Experimental 
5.1. Chemical synthesis 
(E)-1,2-Dibenzyloxy-4-(2-nitroprop-1-en-1-yl)benzene (2). Into a 250 mL round bottomed flask, 3,4-
dibenzyloxybenzaldehyde 1 (7.94 g, 24.95 mmol) and ammonium acetate (1.92 g, 24.95 mmol) were 
dissolved in nitroethane (120 mL) and the mixture heated at reflux for 17h. Nitroethane was then removed 
under reduced pressure. The crude was dissolved in ethyl acetate (25 mL) at 40ºC, cooled to r.t. and 
precipitated with hexane. The solid was filtered and the procedure repeated with the filtrate. Compound 2 
(6.49 g, 75% yield) was obtained as a yellow solid. 
1
H-NMR (400 MHz, CDCl3):  = 2.30 (s, 3H, CH3), 5.21 (s, 2H, CH2), 5.23 (s, 2H, CH2),  6.96-6.98 (m, 
1H, CH), 6.99 (s, 1H, CH), 7.00 (m, 1H, CH),  7.29-7.49 (m, 10H, CH), 7.97 (s, 1H, CH). 
13
C-NMR (100 
MHz, CDCl3):  = 14.1 (CH3), 71.1 (CH2), 71.6 (CH2), 114.4 (CH), 117.0 (CH), 125.0 (CH), 127.27 
(CH), 127.33 (CH), 128.18 (CH), 128.22 (CH), 128.79 (CH), 128.81 (CH), 133.8 (CH), 136.7 (C), 136.9 
 14 
(C), 146.2 (C), 148.7 (C), 150.9 (C=O) ppm. IR (film): νmax: 2923, 2857, 1512, 1308, 1264 cm
-1
. HRMS 
(ESI): calc. for C23H22O4N
+
 ([M+H]
+
): 376.1543; found: 376.1547. 
 
 1-(3,4-bis(benzyloxy)phenyl)propan-2-one (3). In a 3 necked round bottomed flask, nitro compound 2 
(1.24 g, 3.31 mmol), Fe powder (1.11 g, 19.9 mmol, 6 equiv) and FeCl3 (0.12 mg, 0.76 mmol) were 
suspended in ethanol (15 mL). To this mixture water (30 mL) and conc HCl (2 mL) were added and the 
solution was heated at reflux during 5h. The reaction was cooled down and the pH adjusted to 8 with 40% 
NH4OH solution, filtered through celite and extracted with EtOAc. The organic phase was washed with 
water, dried with MgSO4 and evaporated to give a brown crude, which was purified by column 
chromatography (SiO2 / hexanes/ethyl acetate) to afford 3 (0.95 g, 83% yield) as brown oil. 
1
H-NMR (400 MHz, CDCl3):  = 2.07 (s, 3H, CH3), 3.57 (s, 2H, CH2), 5.14 (s, 4H, CH2), 6.72 (dd, J=8,2 
Hz, 1H, CH), 6.78 (d, J=2.0 Hz, 1H, CH), 6.90 (d, J=8.0 Hz, 1H, CH), 7.27-7.39 (m, 6H, CH), 7.41-7.44 
(m, 2H, CH). 
13
C-NMR (100 MHz, CDCl3):  = 29.2 (CH3), 50.6 (CH2), 71.43 (CH2), 71.49 (CH2), 115.4 
(CH), 116.5 (CH), 122.6 (CH), 127.4 (CH), 127.5 (CH), 127.6 (CH), 127.90 (CH), 127.93 (CH), 128.6 
(CH), 137.3 (C), 137.4 (C), 148.3 (C), 149.1 (C), 206.8 (C=O) ppm. IR (film): νmax: 1708, 1512, 1262, 
1137 cm
-1 
HRMS (ESI): calc. for C23H23O3
+
 ([M+H]
+
): 347.1642; found: 347.1651. 
(R,RS)-N-[1-(3,4-Dibenzyloxyphenyl)propan-2-yl]-tert-butylsulfinamide, (R,RS)-4a. In a 2 necked 
250mL round bottomed flask was dissolved (R)-(+)-tert-butylsulfinamide (0.49 g, 4.0 mmol, 2 equiv) in 
anhydrous THF (11 mL). To this solution was added Ti(OEt)4 (4.2mL, 20.2 mmol, 10equiv) and 3 (0.7 g, 
2.0 mmol) in anhydrous THF (13 mL). The brown solution was heated to reflux and monitored by TLC. 
After 5h the reaction was allowed to cool to room temperature. The reaction was then cooled down to -
20ºC, NaBH4 (76 mg, 2.0 mmol, 1 equiv) was added and the reaction was stirred 3h at -20ºC and 
overnight at room temperature. The solution was then filtered through celite and the solvent evaporated 
under reduced pressure. The crude showed a 14:1 diastereomeric ratio by NMR. Column chromatography 
(SiO2, hexane/ethyl acetate) afforded (R,RS)-4a (0.80, 95% yield) as a white solid. 
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M.p.: 91.3- 92.6ºC []D  -53.6 (c 0.7, MeOH). 
1
H-NMR (400 MHz, CDCl3):  =1.12 (d, J=6.3 Hz, 3H, 
CH3), 1.15 (s, 9H, CH3),  2.72 (qd, J=6.6, 13.5 Hz, 2H, CH2), 3.19 (d, J=4.5 Hz, 1H, NH), 3.58 (m, 1H, 
CH), 5.14 (m, 4H, CH2), 6.71 (dd, J=1.9, 8.1 Hz, 1H, CH), 6.82 (d, J= 1.9 Hz, 1H, CH), 6.87 (d, J=8.1 
Hz, 1H, CH), 7.27-7.39 (m, 6H, CH), 7.41-7.46 (m, 4H, CH) ppm. 
13
C-NMR (100 MHz, CDCl3):  = 
20.7 (CH3), 22.7 (CH3), 44.2 (CH2), 51.5 (CH), 55.5 (C), 71.48 (CH2), 71.59 (CH2), 115.5 (CH), 116.7 
(CH), 112.7 (CH), 127.46 (CH), 127.53 (CH), 127.88 (CH), 127.91(CH), 128.58 (CH), 128.59 (CH), 
130.92 (C), 137.4 (C), 137.5 (C), 147.9 (C), 149.1 (C) ppm. IR (film): νmax: 3025, 3033, 2969, 1508, 
1271cm
-1
.
 
HRMS (ESI): Calc. for C27H33NO3SNa
+
 ([M+Na]
+
): 474.2073; found: 474.2071. Calc for 
C54H67N2O6S2
+
 ([2M+H]
+
): 903.4435; found: 903.4424. EA. Calc. for C27H33NO3S: C, 71.81: H, 7.37; N, 
3.10; S, 7.10. found: C, 71.83; H, 7.45; N, 3.36, S, 7.02. 
(S,SS)-N-[1-(3,4-Dibenzyloxyphenyl)propan-2-yl]-tert-butylsulfinamide, (S,SS)-4a. The procedure 
described for (R,RS)-4a, starting from 3 (2.9 g, 8.36 mmol), Ti(OEt)4 (17.4 mL, 83.7 mmol, 10 equiv) and 
(S)-(-)-tert-butylsulfinamide: (2.0 g, 16.8 mmol, 2 equiv), afforded 3.4 g (90% yield) of S,SS)-4a. M.p. 
90.1-90.4 ºC. []D -51.0 (c 0.7, MeOH). The spectroscopic data were identical to (R,RS)-4a. 
(R,RS)-N-[1-(3,4-dibenzyloxyphenyl)propan-2-yl]-N-methyl-tert-butylsulfinamide, (R,RS)-5a. In a 10 
mL round bottomed flask, NaH (4 mg, 0.17 mmol, 2 equiv) was suspended in anhydrous DMF (1.5 mL). 
A solution of 4a (34 mg, 0.075 mmol) in anhydrous DMF (3.5 mL) was added and the reaction stirred 20 
min at room temperature. MeI (28µL, 0.45 mmol, 6 equiv) was added via syringe and the reaction was 
monitored by TLC. When the starting material was consumed, water (10 mL) and EtOAc (10 mL) were 
added. Phases were separated and the organic phase was dried (MgSO4) and evaporated to give a yellow 
oil. Column chromatography (SiO2, hexanes/ethyl acetate) afforded (R,RS)-5a (33 mg, 99% yield) as a 
yellow oil. 
1
H-NMR (400 MHz, CDCl3):  = 1.06 (d, J=6.7 Hz, 3H, CH3), 1.14 (s, 9H, CH3),  2.56 (s, 3H, CH3), 
2.57 (m, 1H, CH2), 2.88 (dd, J=4.8, 13.3Hz, 1H, CH2), 3.38 (m, 1H, CH), 5.13 (s, 2H, CH2), 5.16 (s, 2H, 
CH2), 6.67 (dd, J=2.0, 8.1 Hz, 1H, CH), 6.74 (d, J=2.0 Hz, 1H, CH), 6.86 (d, J=8.2 Hz, 1H, CH) 7.28-
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7.39 (m, 6H, CH), 7.41-7.46 (m, 4H, CH) ppm. 
13
C-NMR (100 MHz, CDCl3):  =17.6 (CH3), 23.7 (CH3), 
26.5 (CH3), 41.1 (CH2), 58.2 (CH), 60.7 (C), 71.6 (CH2), 115.4 (CH), 116.8 (CH), 122.4 (CH), 127.48 
(CH), 127.54 (CH), 127.9 (CH), 128.6(CH), 132.5 (C), 137.5 (C), 137.6 (C), 147.8 (C), 149.0 (C) ppm. 
IR (film): νmax: 3436, 2923, 2872, 1508, 1264 cm
-1
 HRMS (ESI): calc. for C28H36NO3S
+
 ([M+H]
+
): 
466.2410; found: 466.2419. 
(R)-1-(3,4-Bis(benzyloxy)phenyl)propan-2-amine, (R)-6a. In a 250 mL round bottomed flask, a 
solution of 4a (1.73 g, 3.82 mmol) in MeOH (15 mL) was placed. 4M HCl in dioxane (15 mL) was added 
dropwise at room temperature. The reaction was stirred overnight. The solution was extracted with 0.1 M 
HCl (20 mLx5). The aquous phase was treated with 1M NaOH (20 mL) and extracted with EtOAc (15 
mLx5). The organic phases where dried (MgSO4) and evaporated to afford (R)-6a (1.25 g, 94% yield) as 
a colorless oil. 
[]D
 = - 4.7 (c 0.7, MeOH).
 1
H-NMR (400 MHz, MeOD):  = 1.1 (m, 3H, CH3), 2.70 (dd, J=7.8, 13.7Hz, 
1H, CH2), 2.85 (dd, J=6.2, 13.6 Hz, 1H, CH2), 3.43 (m, 1H, CH), 5.12 (s, 2H, CH2), 5.14 (s, 2H, CH2), 
6.78 (dd, J=4.0, 8.1 Hz, 1H, CH), 6.91 (d, J= 1.6 Hz, 1H, CH), 7.01 (d, J=8.2 Hz, 1H, CH), 7.26-7.37 (m, 
6H, CH), 7.41-7.46 (m, 4H, CH) ppm.
 13
C-NMR (100 MHz, MeOD):  = 18.3 (CH3), 41.3 (CH2), 50.3 
(CH), 72.4 (CH2), 72.5 (CH2), 116.8 (CH), 117.7 (CH), 123.5 (CH), 128.67 (CH), 128.74 (CH), 128.92 
(CH), 128.95 (CH), 129.45 (CH), 129.47(CH), 130.6 (C), 138.69 (C), 138.74 (C), 149.7 (C), 150.4 (C) 
ppm. IR (film): νmax: 3045, 2923, 1508, 1258 cm
-1
. HRMS (ESI): Calc. for C23H26O2N
+
 ([M+H]
+
): 
348.1958; found: 348.1957. Calc. for C23H25O2NNa
+
 ([M+Na]
+
): 370.1778; found: 370.1778. 
(S)-1-(3,4-Bis(benzyloxy)phenyl)propan-2-amine, (S)-6a. The procedure described for (R)-6a starting 
from (S)-4a (1.52g, 3.36 mmol) and using 4M HCl in dioxane (15 mL) afforded 0.97 g (83% yield) of 
(S)-6a. []D = +3.1 (c 0.7, MeOH). The spectroscopic data were identical to (R)-6a. 
(R)-Ethyl [1-(3,4-dibenzyloxyphenyl)propan-2-yl]carbamate, (R)-7a. In a 100 mL round bottomed 
flask 6a (1.25 g, 3.58 mmol), 4-(dimethylamino)pyridine (DMAP) (4.38 mg, 0.04mmol, 0.01 equiv) and 
triethylamine (2 mL, 14.33mmol, 4 equiv) were solved in THF (25mL). The stirred solution was cooled 
 17 
to 0º C and a solution of ethyl chloroformate (0.7 mL, 7.17 mmol, 2 equiv) was slowly added. The 
mixture was stirred 6h at room temperature. The residue was dissolved in ether (60mL) and washed with 
water (20mL). The aqueous phase was extracted with diethyl ether (2x25mL) and the combined organic 
phases were washed with water (10 mL), 1N HCl (20 mL) and brine (10 mL), dried (MgSO4) and 
evaporated to obtain a white solid. Crystallization from hot heptane (20 mL) was afforded (R)-7a (1.14 g, 
76% yield) as a white solid. The enantiomeric purity was 99% ee by HPLC. 
M.p. 102.9-104.6. []D = -7.2 (c = 0.7, MeOH). 
1
H-NMR (400 MHz, CDCl3):  = 1.03 (d, J=6.6 Hz, 3H, 
CH3), 1.22 (t, J=7.1Hz, 3H, CH3), 2.57 (dd, J=7.2, 13.5 Hz, 1H, CH2), 2.73 (dd, J=5.0, 13.2Hz, 1H, CH2), 
3.88 (bs, 1H, NH), 4.09 (m, 2H, CH2), 4.43 (bs, 1H, CH), 5.13 (s, 2H, CH2), 5.14 (s, 2H, CH2), 6.68 (dd, 
J= 1.9, 8.1Hz, 1H, CH), 6.77 (s, 1H, CH), 6.86 (d, J=8.1 Hz, 1H, CH), 7.27-7.39 (m, 6H, CH), 7.41-7.46 
(m, 4H, CH) ppm.
13
C-NMR (100 MHz, CDCl3):  =14.6 (CH3), 20.0 (CH3), 42.2 (CH2), 47.7 (CH), 60.5 
(CH2), 71.2 (CH2), 71.3 (CH2), 115.0 (CH), 116.5 (CH), 122.4 (CH), 127.2 (CH), 127.3 (CH), 127.6 (CH), 
127.7 (CH), 128.4 (CH), 131.3 (C), 137.2 (C), 137.4 (C), 147.6 (C), 148.6 (C), 155.8 (C=O). IR (film): 
νmax: 3340, 2971, 1682, 1537, 1513 cm
-1
. HRMS (ESI): calc. for C26H30O4N
+
 ([M+H]
+
): 420.21693; 
found: 420.21723. Calc. for C26H29O4NNa
+
 ([M+Na]
+
): 442.19888; found: 442.19913. Analysis. Calc. for 
C26H29NO4: C, 74.84; H, 6.97; N, 3.34; Found: C, 74.71; H, 7.02; N, 3.75. HPLC: CHIRALCEL AS, 
80% heptane-20% IPA, 0.5 mL/min, λ = 254 nm, t(S) = 14.8 min, t(R) = 17.0 min. Optical purity 99% ee 
 
(S)-Ethyl [1-(3,4-dibenzyloxyphenyl)propan-2-yl]carbamate, (S)-7a. The procedure described for (R)-
7a starting from (S)-6a (0.97 g, 2.78 mmol) and using DMAP (3.4 mg, 0.03 mmol, 0.01 equiv), EtN3 (1.6 mL, 
11.1 mmol, 4 equiv) and ethyl chloroformate (0.53 mL, 5.57 mmol, 2 equiv) afforded 1.02 g (88% yield) of 
(S)-7a.  
M.p. 103.4-104.5 ºC. []D = +5.5 (c = 0.7, MeOH). The spectroscopic data were identical to (R)-7a. 
HPLC: CHIRALCEL AS, 80% heptane-20% IPA, 0.5 mL/min, λ = 254 nm, t(S) = 14.8 min, t(R) = 17.0 
min. Optical purity 99% ee 
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(R)-Ethyl [1-(3,4-dihydroxyphenyl)propan-2-yl]carbamate, (R)-8a. To a solution 7a (1.08 g, 2.58 
mmol) in methanol (37 mL) was added 10wt % Pd/C (0.03 g, 0.1 equiv). The suspension was 
hydrogenated at 10 bar of H2 and 65ºC during 15h. The solution was filtered through celite and 
evaporated to yield (R)-8a (615 mg, 99% of yield) as a brown oil. 
[]D = -14.9 (c = 0.2, MeOH). 
1
H-NMR (400 MHz, MeOD):  = 1.06 (d, J=6.3Hz, 3H, CH3), 1.20 (t, 
J=7.0Hz, 3H, CH3), 2.46 (m, 1H, CH2), 2.65 (m, 1H, CH2), 3.74 (m, 1H, CH), 4.02 (m, 2H, CH2), 6.50 
(m, 1H, CH), 6.63 (m, 1H, CH), 6.66 (m, 1H, CH) ppm. 
13
C-NMR (100 MHz, MeOD ):  = 15.0 (CH3), 
20.4 (CH3), 43.6 (CH2), 49.7 (CH), 61.5 (CH2), 116.1 (CH), 117.4 (CH), 121.7 (CH), 131.8 (C), 144.8 
(C), 146.0 (CH2), 158.5 (C=O) ppm. IR (film): νmax: 3339, 2977, 2929, 1689, 1063 cm
-1
. HRMS (ESI): 
Calc. for C12H18O4N
+
 ([M+H]
+
): 240.1230; found: 240.1230. Calc. for C12H17O4NNa
+
 ([M+Na]
+
): 
262.1050; found: 262.1049. 
(S)-Ethyl [1-(3,4-dihydroxyphenyl)propan-2-yl]carbamate, (S)-8a. The procedure described for (R)-
8a starting from (S)-7a (730 mg, 1.74 mmol) and using Pd/C (18.5 mg, 0.1 equiv) afforded 415 mg (99% 
yield) of (S)-8a.  
[]D = +15.0 (c = 0.2, MeOH). The spectroscopic data were identical to (R)-8a. 
(R)-Ethyl 1-(benzo[d][1,3]dioxol-5-yl)propan-2-ylcarbamate, (R)-9a. To a solution of (R)-8a (668 mg, 
2.79 mmol) and CsCO3 (2.95 g, 8.37 mmol, 3 equiv) in DMF (20 mL) was added BrCH2Cl (0.3 mL, 4.47 
mmol, 1.6 equiv) and the mixture was stirred for 2h at room temperature. The solution was filtered 
through celite and evaporated. The residue was then dissolved in ethyl acetate (200 mL) and washed with 
water (2x25mL) and brine (25mL). The organic layer was dried (MgSO4) filtered and the solvent was 
evaporated to afford (R)-9a (0.69 g, 89% yield) as a white solid. 
[]D = -11.0 (c = 0.2, MeOH). 
1
H-NMR (400 MHz, CDCl3):  = 1.10 (d, J = 6.6Hz, 3H, CH3), 1.23 (t, J = 
7.1Hz, 3H, CH3), 2.60 (dd, J = 7.2,13.5Hz, 1H, CH2), 2.75 (m, 1H, CH2), 3.90 (m, 1H, CH), 4.09 (m, 2H, 
CH2), 4.47 (bs, 1H, NH), 5.93 (m, 2H, CH2), 6.62 (dd, J=1.6, 7.9Hz, 1H, CH), 6.67 (d, J = 1.5Hz, 1H, 
CH), 6.74 (d, J = 8.0Hz, 1H, CH) ppm. 
13
C-NMR (100 MHz, CDCl3):  = 14.8 (CH3), 20.3 (CH3), 
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42.7(CH2), 48.1 (CH), 60.8 (CH2), 101.0 (CH2), 108.3 (CH), 109.9 (CH), 122.5 (CH), 131.9 (C), 146.3 
(C), 147.7 (C), 156.0 (C=O) ppm. IR (film): νmax: 3327, 2968, 2923, 1700, 1245 cm
-1
. HRMS (ESI): 
Calc. for C13H18O4N
+
 ([M+H]
+
): 252.12303; found: 252.12332. Calc. for C13H17O4NNa
+
 ([M+Na]
+
): 
274.1050; found: 274.1053. 
(S)-Ethyl 1-(benzo[d][1,3]dioxol-5-yl)propan-2-ylcarbamate, (S)-9a. The procedure described for (R)-
9a starting from (S)-8a (458 mg, 1.91mmol) and using Cs2CO3 (2.03 g, 5.75 mmol, 3 equiv) in DMF (12 mL). 
and BrCH2Cl: (0.2 mL, 3.06 mmol, 1.6 equiv) afforded 460 mg (95% yield) of (S)-9a.  
[]D = +11.4 (c = 0.2, MeOH). The spectroscopic data were identical to (R)-9a. 
(R)-1-(benzo[d][1,3]dioxol-5-yl)-N-methylpropan-2-amine, (R)-10a, (R)-MDMA. A solution of (R)-9a 
(106 mg, 0.42 mmol) in anh THF (5 mL) was added dropwise to a suspension of LiAlH4 (0.048 g, 1.26 
mmol, 3 equiv) in anh THF (3 mL). The mixture was refluxed with stirring for 4h and then allowed to 
cool to room temperature. The excess LiAlH4 was destroyed by slow addition of water at 0ºC. Ethyl 
acetate was added, extracted with NH4Cl (5 mL) and NaCl (5 mL). The organic layers were dried over 
anhydrous MgSO4, filtered and the solvent was removed under reduced pressure affording (R)-10a (70 
mg, 0.36 mmol) in 85% of yield as a colourless oil. This compound was then dissolved in anhydrous 
diethyl ether (4 mL) and 2M HCl in diethyl ether was added dropwise, yielding the corresponding 
hydrochloride HCl (R)-10a as a white solid. 
[]D = -12.4 (c = 0.6, H2O). 
1
H-NMR (400 MHz, D2O):  = 1.29 (d, J= 6.6Hz, 3H, CH3), 2.71 (s, 3H, 
CH3), 2.86 (dd, J= 7.6, 13.8Hz, 1H, CH2), 2.99 (dd, J= 6.5, 14.0 Hz, 1H, CH2), 3.50 (m, 1H, CH), 5.99 (s, 
2H, CH2), 6.80 (dd, J= 1.7, 8.0 Hz, 1H, CH), 6.86 (d, J= 1.3 Hz, 1H, CH), 6.91 (d, J= 7.9 Hz, 1H, CH) 
ppm. 
13
C-NMR (100 MHz, D2O):  =14.7 (CH3), 29.9 (CH3), 38.4 (CH2), 56.4 (CH2), 101.0 (CH2), 108.6 
(CH), 109.6 (CH), 122.7 (CH), 129.4 (C), 146.2 (C), 147.4 (C). IR (film): νmax: 2955, 2731, 2469, 1482, 
1264.8 cm
-1
. HRMS (ESI): Calc. for C11H16O2N
+
 ([M+H]
+
): 194.1175; found: 194.1177. HPLC (on the 
N-Boc-derivative): CHIRALPAK ADH, 98% heptane, 2% IPA, 0.5 mL/min, λ = 210 nm, t(S) = 21.4 min, 
t(R) = 23.9 min. Optical purity: 99% ee.  
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(S)-1-(benzo[d][1,3]dioxol-5-yl)-N-methylpropan-2-amine, (S)-10a, (S)-MDMA. The procedure 
described for (R)-10a starting from (S)-9a (67 mg, 0.27 mmol) and using LiAlH4 (0.030 g, 0.79 mmol) 
afforded 41 mg (79% yield) of HCl·(S)-10a.  
[]D = +14.2 (c = 0.6, H2O). The spectroscopic data were identical to HCl·(R)-10a. 
 
  
5.2. PC12 cell cultures 
The culture was routinely plated in 92 mm dishes (Nunc) coated with collagen and maintained in 
Dulbecco's modified Eagle's medium (DMEM) supplemented with heat-inactivated 5% fetal bovine 
serum, 10% horse serum, 10 mM HEPES, 2 mM glutamine, 25 UI/ml penicillin and 25 μg/ml 
streptomycin. Cells were cultured to semi-confluency in a humidified 5%CO2 atmosphere at 37 °C and 
medium was changed every 2–3 days. For splitting, cells were dislodged from the dish using a pipette 
with medium, with a portion of these replated onto new culture dishes. Cells were used between passages 
12 and 18. 
To ensure their proper differentiation, cells were mechanically dislodged and seeded (200×10
3
 cells per 
well) onto collagen-coated 24-well plates (Nunc) in medium containing 50 ng/ml nerve growth factor 
(NGF, Upstate Biotechnology, Lake Placid, NY), 1% horse serum, 10 mM HEPES and 2% glutamine in 
DMEM. Under these conditions, the cells developed a neuronal phenotype with neurite outgrowth that 
was already apparent 24 h after seeding. As the expression of nAChR varies during the differentiation 
period, we always used the cells at day 4 of differentiation [55]. 
  
5.3.  Brain membrane preparations 
Binding assays were performed using cortical rat brain tissue. Experimental protocols regarding the use of 
animals in this study were approved by the Animal Ethics Committee of the University of Barcelona 
under the supervision of the Autonomous Government of Catalonia, and in accordance with guidelines of 
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the European Communities Council (86/609/ECC). Efforts were made to minimize suffering and reduce 
the number of animals used. 
Male Sprague-Dawley rats were killed by cervical dislocation (under isoflurane anesthesia). Immediately 
after sacrifice, they were decapitated and the brains rapidly removed from the skull. The cerebellum was 
quickly dissected out and discarded and the rest of brain frozen on dry ice and stored at -80ºC until later 
use. When required, brains were thawed, pooled and homogenized at 4 ºC in 10 volumes of buffer 
consisting of 5 mM Tris-HCl, 320 mM sucrose and protease inhibitors (aprotinin 4.5 μg/μl, 0.1 mM 
PMSF and 1 mM sodium orthovanadate), pH 7.4 using a Polytron homogenizer. The homogenates were 
centrifuged at 15,000 x g for 30 min at 4ºC. The pellets were resuspended in fresh buffer and incubated at 
37ºC for 10 min to remove endogenous neurotransmitters. The protein samples were subsequently re-
centrifuged and washed two additional times. The final pellets (crude membrane preparations) were 
resuspended in 50 mM Tris-HCl buffer plus protease inhibitors and stored at -80 ºC until later use in 
radioligand binding experiments. Protein concentration was determined using the Bio-Rad Protein 
Reagent (Bio-Rad Labs. Inc., Hercules, CA, USA), according to the manufacturer‟s specifications. 
  
5.4. [
3
H]Epibatidine binding 
Competition [
3
H]epibatidine binding experiments were carried out using the membrane preparations 
described above. They were performed in glass tubes containing 1 nM [
3
H]epibatidine (55.5 Ci/mmol), 
the competing drugs ((R)–, (S)– and rac–MDMA) at increasing concentrations and 200 µg of brain 
membranes. The incubation buffer consisted of 50 mM Tris-HCl plus protease inhibitors and incubation 
was carried out for 3 h at 25 ºC. Non-specific binding was determined in the presence of 300 µM nicotine. 
Binding was terminated by rapid filtration under vacuum. 
IC50 values and Hill coefficients were determined fitting the data to the Hill‟s equation using nonlinear 
regression analysis. The inhibition constants (Ki) were calculated from the Cheng-Prusoff equation 
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Ki=IC50/(1+(L/Kd) [56], where L (1 nM) is the total radioligand concentration and Kd is the dissociation 
constant of the radioligand in rat brain (estimated to be 50 pM [57]). 
To measure variations on the surface receptors in PC 12 cells, cells were pretreated for 24h with either 
culture medium (control) or 100 µM (R)-, (S)- or (R,S)-MDMA. Then, a protocol similar to that described 
for [
3
H]epibatidine was used with the difference that cells were incubated with 2 nM [
3
H]epibatidine 
(55.5 Ci/mmol, Perkin Elmer, Boston, MA) for 90 min at 37 °C and non-specific binding was determined 
in the presence of 300 μM nicotine. After incubation, the cells were mechanically dislodged and filtered 
through vacuum. The wells were washed 3 times with ice-cold buffer and the filter was finally washed 
with 4 ml of it. 
In all binding experiments, the radioactivity retained on the filters was counted by liquid scintillation 
spectrometry. Specific binding was defined as the difference between the radioactivity measured in the 
absence (total binding) and in the presence (non-specific binding) of an excess of unlabeled ligand. 
Different determinations were performed in duplicates or triplicates for each experiment with every 
experiment repeated at least three times with similar results. 
 
5.5. Molecular modeling studies: System setup and docking 
To address the binding of MDMA to the 42 receptor, the homology model of the extracellular domains 
of the neuronal rat (4)2(2)3 nAChR subtype constructed by Le Novère et al. was used (PDB ID: 1OLE)  
[49]. The 3D model was refined with the software MOE 2008.10. The stereochemical properties were 
verified and the Ramachandran‟s φ-ψ dihedral plot of residues showed that the backbone torsion angles 
tend to cluster in favourable regions (only 2.1% of residues were found in generously allowed regions or 
disallowed ones), thus supporting the structural model of the receptor. The few residues that were found 
in certain disallowed regions were supervised and manually corrected. Disulfide bonds were created 
between residues Cys167-Cys177 and Cys227-Cys228 of subunit 4 and between Cys154-Cys168 of 
subunit 2. 
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Docking studies were performed for the agonist epibatidine (exo-(+)-1R,2R,4S) and for the two 
enantiomeric forms of MDMA, which were modelled in their protonated form. Ligands were minimized 
using the force field MMFF94x. Docking was carried out with Molecular Operating Environment (MOE) 
2008.10. (Chemical Computing Group). For all cases 30 runs per ligand were performed. Epibatidine was 
used as reference to obtain the best docking parameters. The binding site was defined as the box centered 
in the aromatic moieties of the binding pocket and extended up to around 20 x 22 x 27 Å. To explore for 
alternative binding sites, a blind docking was also carried out. To this end, the box included all the 
protein.  
 
5.6. Molecular modeling studies: Molecular dynamics simulations 
The structural integrity of the binding mode was further explored by means of MD simulations performed 
for the complexes between (R)-MDMA and (S)-MDMA with the receptor. Due to the huge size of the 
whole receptor, simulations were performed for a simplified model consisting of the dimeric model 
containing adjacent 4 and 2 subunits, as derived from the whole 3D model of the pentameric receptor, 
thus containing the binding site at the dimer interface.  
Simulations were run using the PMEMD module of the Amber software package [58]. The parm99SB  
parameters [59] were used for the protein and the gaff force field [60] was used to assign parameters to 
the ligands. The charge distribution of the ligands was refined using RESP charges [61] fitted to the 
B3LYP/6-31G(d) electrostatic potential obtained with Gaussian03 [62]. The system was neutralized and 
immersed in an octahedral box (12 Å) of TIP3P water molecules [63]. Each simulation system thus 
contained the protein-ligand complex, Na
+
 cations and around 18000 water molecules, leading to around 
78500 atoms. 
Starting from the minimized docking positions, a series of 40 ns MD simulations were run for each 
protein-ligand complex. For each simulated system, a geometry optimization was conducted on two steps. 
First, the water molecules and counterions were refined though 3000 steps of steepest descent algorithm 
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followed by 1000 steps of conjugate gradient. Last, the whole system was optimized using 3000 steps of 
steepest descent and 1000 steps of conjugate gradient. Thermalization of the system was performed in the 
NVT ensemble during five steps of 50 ps, using a time step of 1fs and increasing the temperature from 50 
to 298 K. Concomitantly, the inhibitor and the residues that define the binding site were restrained during 
thermalization using a variable restraint force. Thus, a force constant of 25 kcal mol
-1
 Å
-2
 was used in the 
first stage of warming up, and was subsequently decreased by increments of 5 kcal mol
-1
 Å
-2
 in the next 
stages. Following the last stage of thermalization, and prior to the production runs, a short of MD 
simulation of 0.5 ns in the NPT ensemble was conducted in order to allow the system to achieve a stable 
density value at 1 atm. Then a 40 ns trajectory was run using SHAKE to all those bonds involving 
hydrogen atoms, allowing for a timestep of 2 fs, in conjunction with periodic boundary conditions at 
constant volume and temperature (298 K). Constant temperature was achieved by using the Langevin 
thermostat whit a collision frequency of 3 ps
-1
, particle mesh Ewald was used to deal with long range 
electrostatic interactions, and a cutoff of 9 Å was applied for nonbonded interactions. It is worth noting 
that through the complete simulation a restraint force of 5 kcal mol
-1
 Å
-2
 was applied to the residues 
farther than 12 Å from MDMA, which involve interfaces with other subunits or with transmembrane 
region. 
Binding free energies were calculated with the SIETRAJ [64,65] scoring function, which is based in the 
SIE approach and uses parameters that have been fitted to reproduce binding free energies of a data set of 
99 protein-ligand complexes. 500 snapshots sampled during stable parts of the trajectories were examined 
and treated accordingly with the standard SIE protocol. 
 
5.7. QM/MM calculations 
In order to estimate the relative affinity between MDMA enantiomers, the thermodynamic cycles shown 
in Figure 8 were used. For (R)-MDMA, the binding affinity (DGb,aq) can be determined from Eq. 1 (see 
Figure 8A). 
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DGb,aq =DGb,gas +DGsol (P ×R)-DGsol (P)-DGsol (R)       (1) 
where DGb(P ×R)gas  stands for the interaction free energy in the gas phase, and the other terms account 
for the solvation of the receptor (P), ligand (R) and protein-ligand complex (P
.
R). 
With regard to (S)-MDMA, since the interaction is mediated by a water molecule, the binding affinity 
was decomposed in two steps: (i) the formation of the complex between (S)-MDMA and a water 
molecule (left cycle in Figure 8B), and (ii) the binding of the monohydrated (S)-MDMA to the receptor 
(right cycle in Figure 8B). Let us note that the formation of the complex between (S)-MDMA in aqueous 
solution and a water molecule in liquid water does not involve any change in free energy (i.e., 
DGb(S ×H2O)aq = 0). Accordingly, the binding free energy can be determined from Eq, 2. 
DGb,aq = DGb(P ×S × H2O)aq = DGb(S × H2O)gas +DGb(P ×S × H2O)gas +
                                      DGsol (P ×S ×H2O)-DGsol (P)-DGsol (S)-DGsol (H2O)
   (2) 
The relative affinity between enantiomers can be estimated as noted in Eq (3), which benefits from the 
cancellation of most of the terms included in Eqs. (1) and (2). 
 
DDGb,aq = DGb(S × H2O)gas +DGb(P ×S × H2O)gas +DGsol (P ×S ×H2O)-DGsol (H2O)
                -DGb(P ×R)gas -DGsol (P ×R)
   (3) 
The free energy change due to the formation of the monohydrated (S)-MDMA
.
H2O in the gas phase (
DGb(S ×H2O)gas ) was determined from quantum mechanical (QM) calculations at the MP2/6-31+G(d) 
level, including the basis set superposition error correction [66], and the thermal and entropic 
contributions estimated by using the harmonic oscillator-rigid rotor model. The contribution due to the 
formation of the ligand-protein complex (DGb(P ×S ×H2O)gas;  DGb(P ×R ×H2O)gas) was determined from 
hybrid quantum mechanical/molecular mechanical (QM/MM) calculations. To this end, the ligand was 
treated at the QM level and all the residues located at less than 15 Å of the ligand were treated classically. 
Accordingly, the electrostatic term accounts for the QM interaction (determined at the MP2/6-31+G(d) 
level) of the ligand with the set of point charges of the residues included in the MM region. The van der 
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Waals term was determined using the 6-12 expression as implemented in AMBER. Calculations were 
performed for a set of 25 snapshots taken evenly along the last 10 ns of the trajectories and averaging the 
electrostatic and van der Waals components of the individual snapshots. The contribution due to 
thesolvation of the complexes (DGsol (P ×S ×H2O);  DGsol (P ×R)) was assumed to cancel. This assumption is 
motivated by i) the fact that QM/MM calculations were performed using a common set of residues within 
the sphere (15 Å) that embodies the binding site for the two enantiomers of MDMA, ii) the close 
structural resemblance of the MM subsystems in the simulations performed for the two enantiomers, 
indicating the lack of relevant structural rearrangements, and iii) the burial of the water molecule bound to 
(S)-MDMA in the binding cavity. It must be noted, however, that the reliability of this assumption was 
further supported by MM/PBSA computations performed for the subsystems used in QM/MM 
calculations. Finally, the solvation free energy of the water molecule was corrected to take into account 
the contributions due to the changes in standard states in the process of transferring a water molecule 
from the gas phase (at 1 atm and 298 K) to bulk water [67]. 
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Legends to Schemes and Figures 
 
Scheme 1. Molecular structure of  epibatidine and (R)-MDMA. 
Scheme 2. Diastereoselective synthesis of sulfinamides 4. 
Scheme 3. Synthesis of (R)-MDMA from diastereomerically pure sulfinamide 4a. 
Figure 1. Representative competition curves showing the inhibition of [
3
H]epibatidine binding by (R)-, 
(S)- and (R,S)-MDMA in membranes from rat brain. Membranes were incubated for 2 h at 4°C with 2 nM 
[3H]epibatidine in the absence or the presence of increasing concentrations of MDMA. Inhibition curves 
were calculated using the nonlinear least squares method and adjusted to a one-site model. Data represent 
means of duplicates and the experiments were performed three times with similar results. 
Figure 2. [
3
H]-Epibatidine binding sites after treatment with (R)-, (S)- and rac-MDMA (100 μM). PC 12 
cells were incubated with amphetamine derivatives over 24 h and radioligand binding was performed on 
intact cells in culture. Data represent the means ± SEM of three separate experiments carried out in 
triplicates (**p<0.01, ***p<0.001 vs. control cells; ##p<0.01, vs. (R)-MDMA). 
Figure 3. (A) Best pose (BP) of (R)-MDMA in the binding site of the dimeric 3D model of the42 
receptor. (B) Representation of the alternative pose (AP) characterized by the distinct arrangement of the 
methylenedioxybenzene ring in the binding pocket. The backbone of the two chains in the dimer is shown 
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in blue ( subunit) and green ( subunit). Trp184, Cys227 and Cys228 are shown as blue sticks, and 
Phe143 as green sticks  (R)-MDMA is shown as orange sticks, and epibatidine as white sticks. 
Figure 4. Representation of (R)-MDMA in the binding site of the dimeric 3D model of the42 receptor 
as obtained from MD-BP simulations. Selected residues pertaining to the snapshots collected at 20, 30 
and 40 ns of the MD trajectory are shown as blue ( subunit) and green ( subunit) sticks, and the ligand 
is shown as orange sticks. 
Figure 5. Representation of the closest contacts between the methyl group attached to the ethylamine 
chain of (R)- and (S)-MDMA in the receptor binding site. Selected residues pertaining to the snapshot 
collected at the end of the MD-BP trajectories are shown as blue and green sticks. (R)- and (S)-MDMA 
are shown as orange and yellow sticks, respectively, and the water molecule that mediates the interaction 
of the amine nitrogen in (S)-MDMA is shown as a red sphere. 
 
 
 
Table 1. Experimental binding parameters (IC50, inhibition constant, Ki, and Hill’s 
coefficient, nH) determined for the binding of MDMA to the 42 nAChR subtype 
(SEM: standard error of the mean).  
 
 
 
 
 
 
a
 Significantly different from the value of 1 with p<0.001. 
 
 Ligand IC50  SEM  (M)
 
 Ki   SEM (M)  nH  SEM 
(R)-MDMA 13.45  2.76 0.63  0.16 1.02  0.01 
(S)-MDMA 172.65  34.58 8.21  2.02 0.75  0.11a  
rac-MDMA 30.40  6.65 1.44  0.54 1.03  0.04 
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